SCHEDULE 13G/A: Armistice Capital and Steven Boyd Maintain 4.99% Stake in Pasithea Therapeutics Corp.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a continued beneficial ownership of 4.99% of Pasithea Therapeutics Corp.'s common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") filed an Amendment No. 2 to Schedule 13G with the SEC.
• The filing reports their beneficial ownership in Pasithea Therapeutics Corp. (the "Issuer"), specifically its Common Stock, par value $0.0001 per share.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 142,082 shares of the Issuer's Common Stock.
• This ownership represents 4.99% of the Issuer's outstanding class of securities.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The Reporting Persons hold shared voting power and shared dispositive power over all 142,082 shares.
• The shares were acquired and are held in the ordinary course of business and are not for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 5

Explanation: Neutral. This document is a factual disclosure of beneficial ownership and does not contain information related to the company's financial performance, operational updates, or strategic initiatives that would typically influence sentiment. The maintenance of a significant stake by an institutional investor could be seen as mildly positive, but the filing itself is routine.

Positives

• A significant institutional investor, Armistice Capital, and its principal, Steven Boyd, maintain a substantial stake (4.99%) in Pasithea Therapeutics Corp., which could be interpreted as a continued vote of confidence in the company.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, indicating a passive investment approach which may reduce concerns about potential activist interventions.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the Issuer's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics, but rather reflects an investment decision within the healthcare or biotechnology sector where Pasithea Therapeutics Corp. operates.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional holding, which may offer a degree of confidence to other shareholders by indicating a major investor's continued interest in the company.

Key Dates

Keywords

Pasithea Therapeutics Corp., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Institutional Investor